$1.9 Billion is the total value of Camber Capital Management LP's 34 reported holdings in Q3 2019. The portfolio turnover from Q2 2019 to Q3 2019 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BKD | BROOKDALE SENIOR LIVING | $94,750,000 | +5.1% | 12,500,000 | 0.0% | 4.98% | +18.6% | |
| AGN | ALLERGAN PLCcall | $84,145,000 | +0.5% | 500,000 | 0.0% | 4.42% | +13.4% | |
| HCA | HCA HEALTHCARE INC | $72,252,000 | -10.9% | 600,000 | 0.0% | 3.80% | +0.5% | |
| ASND | ASCENDIS PHARMA A Ssponsored adr | $62,608,000 | -16.4% | 650,000 | 0.0% | 3.29% | -5.6% | |
| MYL | MYLAN N Vcall | $59,340,000 | +3.9% | 3,000,000 | 0.0% | 3.12% | +17.2% | |
| MNTA | MOMENTA PHARMACEUTICALS INC | $45,360,000 | +4.1% | 3,500,000 | 0.0% | 2.38% | +17.4% | |
| THOR | SYNTHORX INC | $30,297,000 | +20.4% | 1,862,116 | 0.0% | 1.59% | +35.8% | |
| GSK | GLAXOSMITHKLINE PLCsponsored adr | $21,340,000 | +6.6% | 500,000 | 0.0% | 1.12% | +20.3% | |
| STRO | SUTRO BIOPHARMA INC | $5,454,000 | -20.1% | 600,000 | 0.0% | 0.29% | -9.7% | |
| SGRY | SURGERY PARTNERS INC | $1,182,000 | -9.3% | 160,084 | 0.0% | 0.06% | +1.6% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| TEVA PHARMACEUTICALS INDS LTD | 34 | Q3 2023 | 9.7% |
| BROOKDALE SR LIVING INC | 32 | Q3 2023 | 5.0% |
| PERRIGO CO PLC | 29 | Q3 2023 | 7.1% |
| TENET HEALTHCARE CORP | 28 | Q3 2023 | 8.5% |
| NEKTAR THERAPEUTICS | 28 | Q1 2022 | 9.8% |
| UNIVERSAL HLTH SVCS INC | 25 | Q3 2023 | 9.9% |
| MYRIAD GENETICS INC | 24 | Q3 2023 | 5.0% |
| SAREPTA THERAPEUTICS INC | 23 | Q3 2023 | 6.0% |
| MYLAN NV | 21 | Q3 2020 | 10.1% |
| AMAG PHARMACEUTICALS INC | 21 | Q3 2020 | 4.0% |
View Camber Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC | February 02, 2023 | ? | ? |
| Solid Biosciences Inc. | December 12, 2022 | ? | ? |
| AVROBIO, Inc. | February 14, 2022 | ? | ? |
| COLLEGIUM PHARMACEUTICAL, INC | February 14, 2022 | ? | ? |
| AMAG PHARMACEUTICALS, INC. | February 16, 2021 | ? | ? |
| Atara Biotherapeutics, Inc. | February 16, 2021 | ? | ? |
| Change Healthcare Inc. | February 16, 2021 | ? | ? |
| GLYCOMIMETICS INC | February 16, 2021 | ? | ? |
| Clovis Oncology, Inc. | February 14, 2020 | ? | ? |
| Cyclerion Therapeutics, Inc. | February 14, 2020 | ? | ? |
View Camber Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| SC 13G | 2023-10-30 |
View Camber Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.